Full Prescribing Information | Important Safety Information | View this e-mail online  
 
 
NOW AVAILABLE!
 
 
  VISTOGARD® (uridine triacetate) oral granules  
 
  DOSAGE AND ADMINISTRATION  
 
  Recommended Dosage  
 
 
Adults: 10 g (1 packet) orally every 6 hours for 20 doses, without regard to meals.
 
Pediatric: 6.2 g/m2 of body surface area (not to exceed 10 g per dose) orally every 6 hours for 20 doses, without regard to meals. See the full prescribing information for body surface area-based dosing.
 
 
 
vistogard.com   For more information,
please visit www.vistogard.com
 
 
  Reference: 1. Vistogard  [prescribing information]. BTG International Inc; 2015.  
 
  Important Safety Information  
 
 
 
In clinical studies, adverse reactions occurring in >2% of patients receiving VISTOGARD included vomiting (10%), nausea (5%), and diarrhea (3%).
 
One person receiving uridine triacetate experienced grade 3 nausea and vomiting.
 
VISTOGARD was discontinued for adverse reactions in 2 (1.4%) patients.
 
 
  For more detailed information, please download the full Prescribing Information here.  
 
 
   
 
 
  © 2016 BTG International Inc. All rights reserved.  
 
  © Wellstat Therapeutics Corporation.  
 
  NA-VIS-2016-0708  
 
  BTG and the BTG roundel logo are registered trademarks of BTG International Ltd.  
 
  BTG Specialty Solutions CenterTM is a trademark of BTG International Ltd.  
 
  VISTOGARD® and the VISTOGARD® logo are registered trademarks of Wellstat Therapeutics Corporation.  
 
  The Wellstat logo is a registered trademark of Wellstat Therapeutics Corporation.  
 
  You are subscribed as %%EMAIL%%
To unsubscribe from promotional messages please click here
For unsubscribe problems, please reply to this e-mail
 
 
  All Cancer Therapy Advisor promotional email are sent from the domain "mail.cancertherapyadvisor.com".
When configuring e-mail or spam filter rules, please use this domain name.
 
 
  © 2016 Haymarket Media Inc
114 West 26th St 4th floor
New York, NY 10001